Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2B, Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-ranging, Multicentre Study to Investigate the Efficacy, Safety and Tolerability of the mGluR5 Negative Allosteric Modulator ADX10059 for the Prevention of Migraine

NCT00820105 is registered in ClinicalTrials.gov with Addex Pharma S.A. as lead sponsor.

NCT NCT00820105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00820105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2B, Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-ranging, Multicentre Study to Investigate the Efficacy, Safety and Tolerability of the mGluR5 Negative Allosteric Modulator ADX10059 for the Prevention of Migraine
Lead sponsor
Addex Pharma S.A.
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2008
Completion date
Not reported
Enrollment
350 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

migraine